What 8 Analyst Ratings Have To Say About Sangamo Therapeutics
Portfolio Pulse from Benzinga Insights
Sangamo Therapeutics (NASDAQ:SGMO) has received various analyst ratings in the last quarter, with 2 bullish, 4 somewhat bullish, and 2 indifferent. Over the past 3 months, 8 analysts have offered 12-month price targets for the company, with an average price target of $5.5, a decrease of 38.89% from the previous average price target of $9.00.
November 06, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sangamo Therapeutics has received mixed analyst ratings, with a decrease in the average price target, which could potentially impact the stock's performance.
Analyst ratings can significantly influence investor sentiment and stock performance. The decrease in the average price target suggests a potential negative short-term impact on Sangamo Therapeutics' stock.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100